Last reviewed · How we verify
FF/VI 100/25 Inhalation Powder NDPI
FF/VI 100/25 Inhalation Powder NDPI is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation for chronic obstructive pulmonary disease.
FF/VI is a combination of fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) that reduces airway inflammation and improves bronchodilation for chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.
At a glance
| Generic name | FF/VI 100/25 Inhalation Powder NDPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Beta-2 adrenergic receptor; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Fluticasone furoate acts as a potent inhaled corticosteroid that suppresses inflammatory responses in the airways, reducing mucus production and airway edema. Vilanterol is a long-acting beta-2 agonist that stimulates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and improved airflow. Together, they provide both anti-inflammatory and bronchodilatory effects in a single inhalation powder formulation.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nasopharyngitis
Key clinical trials
- Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). (PHASE4)
- A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD (PHASE3)
- An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma. (PHASE3)
- A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FF/VI 100/25 Inhalation Powder NDPI CI brief — competitive landscape report
- FF/VI 100/25 Inhalation Powder NDPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about FF/VI 100/25 Inhalation Powder NDPI
What is FF/VI 100/25 Inhalation Powder NDPI?
How does FF/VI 100/25 Inhalation Powder NDPI work?
What is FF/VI 100/25 Inhalation Powder NDPI used for?
Who makes FF/VI 100/25 Inhalation Powder NDPI?
What drug class is FF/VI 100/25 Inhalation Powder NDPI in?
What development phase is FF/VI 100/25 Inhalation Powder NDPI in?
What are the side effects of FF/VI 100/25 Inhalation Powder NDPI?
What does FF/VI 100/25 Inhalation Powder NDPI target?
Related
- Drug class: All Inhaled corticosteroid/long-acting beta-2 agonist combination drugs
- Target: All drugs targeting Beta-2 adrenergic receptor; glucocorticoid receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory/Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Compare: FF/VI 100/25 Inhalation Powder NDPI vs similar drugs
- Pricing: FF/VI 100/25 Inhalation Powder NDPI cost, discount & access